SELENON and glioma: To strengthen our findings, we conducted analyses in an independent cohort, ZN-Glioma, which reaffirmed that high SEPN1 expression is an adverse prognostic factor for glioma patients (Fig 2I–2K and S10, S11 Tables in S1 File).